PTC Therapeutics, Inc. provided earnings guidance for the year 2022. For the year 2022, the company anticipates total revenues for the full year 2022 to be between $700 and $750 million. The company anticipated net product revenues for the DMD franchise for the full year 2022 to be between $475 and $495 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.21 USD | -0.79% | +0.20% | -8.53% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.53% | 1.95B | |
-1.51% | 105B | |
+3.22% | 97.5B | |
+1.86% | 22.19B | |
-16.53% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.09% | 14.52B | |
+5.47% | 14.09B | |
+28.85% | 10.99B |
- Stock Market
- Equities
- PTCT Stock
- News PTC Therapeutics, Inc.
- PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2022